Truist Financial Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $14.00
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price objective lowered by equities research analysts at Truist Financial from $18.00 to $14.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price objective suggests a potential upside of 262.69% […]
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price objective lowered by equities research analysts at Truist Financial from $18.00 to $14.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price objective suggests a potential upside of 262.69% […]
